Kao
This article was originally published in The Rose Sheet
Executive Summary
Japanese beauty firm will respond to high commodity prices and consumer concern over economic downturn by adjusting product prices, launching new products with "high added value" for budget-conscious shoppers, and conducting in-store merchandising initiatives that respond to changes in consumer spending habits, company states in first quarter earnings release issued July 28. Firm's beauty care sales for the quarter decreased 4.6% to $1.33 bil. (¥1=$.009) Intensifying competition in the U.S. market and sluggish consumer spending hampered beauty sales in North America and Europe, though John Frieda and Guhl hair care brands saw "solid" sales in Europe, Kao notes. Japanese beauty sales decreased 1.9% to $986.3 mil. due to lower sales of prestige cosmetics. Kao's net sales fell .4% to $2.98 bil. and net income increased 31.4% to $160.6 mil...
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.